Pharmaceutical Development and Technology,
Год журнала:
2024,
Номер
29(2), С. 123 - 130
Опубликована: Фев. 7, 2024
This
study
was
to
construct
a
nanovesicle
delivery
system
improve
the
loading
efficiency
and
stability
of
ORI
for
treatment
nonalcoholic
fatty
liver
disease
(NAFLD).
nanovesicles
(NVs)
exerted
narrow
size
distribution
(195.6
±
11.49
nm)
high
entrapment
(84.46
1.34%).
In
vitro
cell
studies
demonstrated
that
NVs
enhanced
cellular
uptake
reduced
lipid
over-accumulation
total
cholesterol
levels
in
NAFLD
model.
At
same
time,
vivo
proved
that,
compared
with
normal
group,
model
group
mice
showed
decrease
body
weight,
significant
increase
index
(6.71
0.62,
p
<
0.01),
symptoms
accumulation,
vesicles,
tissue
fibrosis.
Compared
after
high-dose
intervention,
gained
decreased
(4.69
0.55,
hepatic
droplet
vacuoles,
accumulation
(reduced
oil
red
area,
0.001),
alleviated
degree
fibrosis
blue
collagen
0.001).
conclusion,
ORI/HP-β-CD/H9-HePC
specific
improved
therapeutic
effects,
nano
drug
provides
promising
strategy
encapsulation
effectively
alleviate
process
NAFLD.
Current Molecular Pharmacology,
Год журнала:
2022,
Номер
16(7)
Опубликована: Дек. 2, 2022
In
recent
years,
attention
has
increasingly
focused
on
herbal
medicines
and
their
bioactive
components
attributed
to
multi-target
pharmacological
activity
low
side
effects.
Oridonin
is
a
natural
diterpenoid
extracted
from
the
traditional
Chinese
herb
one
of
main
active
Rabdosia
rubescens.
Modern
studies
have
shown
that
oridonin
anti-tumor,
anti-bacterial,
anti-inflammatory,
anti-oxidant,
cardiovascular
protective,
immunomodulatory,
other
Based
published
literature
in
we
outline
activities
oridonin,
aiming
provide
theoretical
basis
for
design
development
new
oridonin-based
drugs,
as
well
facilitate
process
clinical
use.
Pharmaceutical Development and Technology,
Год журнала:
2024,
Номер
29(2), С. 123 - 130
Опубликована: Фев. 7, 2024
This
study
was
to
construct
a
nanovesicle
delivery
system
improve
the
loading
efficiency
and
stability
of
ORI
for
treatment
nonalcoholic
fatty
liver
disease
(NAFLD).
nanovesicles
(NVs)
exerted
narrow
size
distribution
(195.6
±
11.49
nm)
high
entrapment
(84.46
1.34%).
In
vitro
cell
studies
demonstrated
that
NVs
enhanced
cellular
uptake
reduced
lipid
over-accumulation
total
cholesterol
levels
in
NAFLD
model.
At
same
time,
vivo
proved
that,
compared
with
normal
group,
model
group
mice
showed
decrease
body
weight,
significant
increase
index
(6.71
0.62,
p
<
0.01),
symptoms
accumulation,
vesicles,
tissue
fibrosis.
Compared
after
high-dose
intervention,
gained
decreased
(4.69
0.55,
hepatic
droplet
vacuoles,
accumulation
(reduced
oil
red
area,
0.001),
alleviated
degree
fibrosis
blue
collagen
0.001).
conclusion,
ORI/HP-β-CD/H9-HePC
specific
improved
therapeutic
effects,
nano
drug
provides
promising
strategy
encapsulation
effectively
alleviate
process
NAFLD.
